vTv Therapeutics (VTVT) Operating Expenses (2014 - 2026)

vTv Therapeutics has disclosed Operating Expenses across 13 years of filings, most recently posting $13.9 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 80.42% year-over-year to $13.9 million; the TTM figure through Jun 2026 stood at $46.1 million (up 79.77% YoY), while the FY2025 annual figure was $32.8 million, up 30.21% from the prior year.
• Operating Expenses came in at $13.9 million for Q2 2026 at vTv Therapeutics, up from $13.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $13.9 million in Q2 2026 to a low of $4.0 million in Q2 2022.
• Average Operating Expenses over 5 years is $7.5 million, with a median of $6.9 million recorded in 2024.
• Year-over-year, Operating Expenses slumped 42.87% in 2022 and surged 108.77% in 2026.
• Over 5 years, Operating Expenses stood at $6.4 million in 2022, then dropped by 25.9% to $4.7 million in 2023, then increased by 4.29% to $4.9 million in 2024, then jumped by 60.62% to $7.9 million in 2025, then soared by 76.66% to $13.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $13.9 million in Q2 2026, $13.6 million in Q1 2026, and $7.9 million in Q4 2025.